Robert L. Page II Pharm.D. M.S.P.H. FAHA, Chair of the writing group for the American Heart Association Scientific Statement: Medical Marijuana, Recreational Cannabis, and Cardiovascular Health (August 2020) and professor in the department of clinical pharmacy and the department of physical medicine/rehabilitation at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences in Aurora, Colorado.

Offering perspective on AHA Scientific Sessions 2020 Presentations P1916 and P380
copyright American Heart Association 2020


"Patients must be transparent with all their providers. And because exactly as we see, particularly the new data with regards to stroke. In my mind, even a small percentage increase in stroke is not acceptable. We've been evaluating the potential drug drug interactions that do exist with cannabis, and antiplatelet agents. And so these data do are suggestive of the potential mechanism that cannabis has at the CBD, one receptor, and so therefore, patients need to be disclosing this in order to minimize adverse events following for example, a PCI or an individual who has had a myocardial infarction in the past. It's crucial that this be communicated as we elucidate the particular potential drug interactions and mechanisms that exist with cardiovascular medications. Patients must communicate this prior way prior to any procedure, cardiac procedure that is going to be conducted."